This study looks at how well a new medicine, efgartigimod PH20 SC, works for adults with new-onset generalized myasthenia gravis (gMG). gMG is a condition where muscles get weak because the immune system attacks them. "New-onset" means the person has had symptoms for less than a year. This study lasts about 58 weeks.
Key Points:
- The study lasts for approximately 58 weeks, including 51 weeks of treatment.
- Participants need to have had generalized MG symptoms for less than 1 year.
- Participants shouldn't have used certain medicines or had specific surgeries related to gMG before the study.